Problems Occurring Late after Poliomyelitis: A Rehabilitation Approach

Critical Reviews in Physical and Rehabilitation Medicine

Volumn 15, Issue 3-4, 2003, Pages 295-308

  McNaughton, Harry K ^a   McPherson, Kathryn M ^b  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Neurological impairment; Poliomyelitis; Post polio syndrome

Indexed keywords

AMANTADINE; CHOLINESTERASE INHIBITOR; CORTICOSTEROID; PLACEBO; POLIOMYELITIS VACCINE; PREDNISONE; PYRIDOSTIGMINE;

CLINICAL FEATURE; CLINICAL TRIAL; DISABILITY; DRUG EFFICACY; ELECTROMYOGRAM; FOLLOW UP; HUMAN; MEDICAL ASSESSMENT; PATHOPHYSIOLOGY; POLIOMYELITIS; POLIOMYELITIS VIRUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME; VACCINATION;

EID: 0842282625     PISSN: 08962960     EISSN: None     Source Type: Journal    
DOI: 10.1615/CritRevPhysRehabilMed.v15.i34.60     Document Type: Review

References (41)

1. World Health Organization. Poliomyelitis fact sheet. Available at: http://www.who.int/health-topics/poliomyelitis.htm. Accessed: July 1, 2002.
2. Kumar S. Polio epidemic hits Uttar Pradesh. Br Med J 2002; 325(7365):617.
3. World Health Organization. Europe achieves historic milestone as region is declared polio-free [press release]. Geneva, Switzerland: World Health Organization; 2002.
4. Joce R, Wood D, Brown D, Begg N. Paralytic poliomyelitis in England and Wales, 1985-91. Br Med J 1992; 305(6845):79-82.
5. Oostvogel PM, van Wijngaarden JK, van der Avoort HG, et al. Poliomyelitis outbreak in an unvaccinated community in the Netherlands, 1992-93. Lancet 1994; 344(8923):665-670.
6. Dalakas MC. The post-polio syndrome as an evolved clinical entity. Definition and clinical description. Ann N Y Acad Sci 1995; 753:68-80.
7. Wiechers D. Electrophysiology of acute polio revisited. Utilizing newer EMG techniques in vaccine-associated disease. Ann N Y Acad Sci 1995; 753:111-119.
8. Daube JR, Windebank AJ, Litchy WJ. Electrophysiologic changes in neuromuscular function over five years in polio survivors. Ann N Y Acad Sci 1995; 753:120-128.
9. Dalakas MC. Post-polio syndrome 12 years later. How it all started. Ann N Y Acad Sci 1995; 753:11-18.
10. Anderson AD, Levine SA, Gellert H. Loss of ambulatory ability in patients with old anterior poliomyelitis. Lancet 1972; 2(7786):1061-1063.
11. Mulder DW, Rosenbaum RA, Layton DD, Jr. Late progression of poliomyelitis or forme fruste amyotrophic lateral sclerosis? Mayo Clin Proc 1972; 47(10):756-761.
12. Muir P, Nicholson F, Spencer GT, et al. Enterovirus infection of the central nervous system of humans: lack of association with chronic neurological disease. J Gen Virol 1996; 77(pt 7):1469-1476.
13. Dalakas MC. Pathogenetic mechanisms of post-polio syndrome: morphological, electrophysiological, virological, and immunological correlations. Ann N Y Acad Sci 1995; 753:167-185.
14. Ramlow J, Alexander M, LaPorte R, Kaufmann C, Kuller L. Epidemiology of the post-polio syndrome. Am J Epidemiol 1992; 136(7):769-786.
15. Mulder DW. Clinical observations on acute poliomyelitis. Ann N Y Acad Sci 1995; 753:1-10.
16. Windebank AJ, Litchy WJ, Daube JR. Prospective cohort study of polio survivors in Olmsted County, Minnesota. Ann N Y Acad Sci 1995; 753:81-86.
17. Howard RS, Wiles CM, Spencer GT. The late sequelae of poliomyelitis. Q J Med 1988; 66(251):219-232.
18. Kidd D, Howard RS, Williams AJ, Heatley FW, Panayiotopoulos CP, Spencer GT. Late functional deterioration following paralytic poliomyelitis. Q J Med 1997; 90(3):189-196.
19. Carson AJ, Ringbauer B, MacKenzie L, Warlow C, Sharpe M. Neurological disease, emotional disorder, and disability: they are related: a study of 300 consecutive new referrals to a neurology outpatient department. J Neurol Neurosurg Psychiatry 2000; 68(2):202-206.
20. Wade DT. Medically unexplained disability - a misnomer, and an opportunity for rehabilitation. Clin Rehabil 2001; 15(4):343-347.
21. Allanson J, Bass C, Wade DT Characteristics of patients with persistent severe disability and medically unexplained neurological symptoms: a pilot study. J Neurol Neurosurg Psychiatry 2002; 73(3):307-309.
22. Rekand T, Karlsen B, Langeland N, Aarli JA. Long-term follow-up of patients with nonparalytic poliomyelitis. Arch Phys Med Rehabil 2002; 83(4):533-537.
23. Grimby G, Stalberg E, Sandberg A. An 8 year longitudinal study of muscle strength, muscle fiber size, and dynamic electromyogram in individual with late polio. Muscle Nerve 1998; 21(11):1428-1437.
24. Dinsmore S, Dambrosia J, Dalakas MC. A double-blind, placebo-controlled trial of high-dose prednisone for the treatment of post-poliomyelitis syndrome. Ann N Y Acad Sci 1995; 753:303-313.
25. Trojan DA, Collet JP, Shapiro S, et al. A multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome. Neurology 1999; 53(6):1225-1233.
26. Stein DP, Dambrosia JM, Dalakas MC. A double-blind, placebo-controlled trial of amantadine for the treatment of fatigue in patients with the post-polio syndrome. Ann N Y Acad Sci 1995; 753:296-302.
27. Agre JC. The role of exercise in the patient with post-polio syndrome. Ann N Y Acad Sci 1995; 753:321-334.
28. Halstead LS, Gawne AC, Pham BT. National rehabilitation hospital limb classification for exercise, research, and clinical trials in post-polio patients. Ann N Y Acad Sci 1995; 753:343-353.
29. a. Peach PE, Olejnik S. Effect of treatment and noncompliance on post-polio sequelae. Orthopaedics 1991; 14:1199-1203.
30. Bach JR, Tilton M. Pulmonary dysfunction and its management in post-polio patients. Neurorehabilitation 1997; 8(2):139-153.
31. World Health Organization. International Classification of Impairments, Disabilities, and Handicaps. Geneva, Switzerland: World Health Organization; 1980.
32. World Health Organization. ICIDH-2: International Classification of Impairments, Activities and Participation. A manual of dimensions of disablement and functioning. Beta-2 draft for field trials. Geneva, Switzerland: World Health Organization; 1999.
33. Bickenbach JE, Chatterji S, Badley, EM, Ustun TB. Models of disablement, universalism and the international classification of impairments, disabilities and handicaps. Soc Sci Med 1999; 48(9):1173-1187.
34. World Health Organization. International Classification of Functioning, Disability and Health. Geneva, Switzerland: World Health Organization; 2001.
35. McPherson KM, Brander P, Taylor WJ, McNaughton HK. Living with arthritis - what is important? Disab Rehabil 2001; 23(16):706-721.
36. Whiteneck GG. Measuring what matters: key rehabilitation outcomes. Arch Phys Med Rehabil 1994; 75(10):1073-1076.
37. Maynard FM. Managing the late effects of polio from a life-course perspective. Ann N Y Acad Sci 1995; 753:354-360.
38. Wade DT. Measurement in neurological rehabilitation. Oxford, UK: Oxford University Press; 1992.
39. McNaughton H, McPherson K, Falkner E, Taylor W. Impairment, disability, handicap and participation in post-poliomyelitis subjects. Int J Rehabil Res 2001; 24(2):133-136.
40. Myers J, McPherson K, Taylor W, Weatherall M, McNaughton H. Duration of condition is unrelated to health-state valuation on the EuroQoL. Clin Rehabil 2003; 17:209-215.
41. Taylor WJ, McPherson KM. Measuring quality of life. Aust J Rehabil Counsel 1992; 5:69-77.